Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.
2.

Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery.

Bellocq NC, Pun SH, Jensen GS, Davis ME.

Bioconjug Chem. 2003 Nov-Dec;14(6):1122-32.

PMID:
14624625
3.
4.

Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles.

Pun SH, Tack F, Bellocq NC, Cheng J, Grubbs BH, Jensen GS, Davis ME, Brewster M, Janicot M, Janssens B, Floren W, Bakker A.

Cancer Biol Ther. 2004 Jul;3(7):641-50. Epub 2004 Jul 9.

PMID:
15136766
5.

Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.

Bartlett DW, Davis ME.

Bioconjug Chem. 2007 Mar-Apr;18(2):456-68. Epub 2007 Feb 28.

6.

Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.

Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y.

Eur J Pharm Biopharm. 2008 Nov;70(3):718-25. doi: 10.1016/j.ejpb.2008.06.026. Epub 2008 Jul 4.

PMID:
18647651
7.

Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles.

Carmona S, Jorgensen MR, Kolli S, Crowther C, Salazar FH, Marion PL, Fujino M, Natori Y, Thanou M, Arbuthnot P, Miller AD.

Mol Pharm. 2009 May-Jun;6(3):706-17. doi: 10.1021/mp800157x.

PMID:
19159285
9.

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21. Epub 2007 Mar 22.

10.

Proof of RNA interference in humans after systemic delivery of siRNAs.

Kurreck J.

Angew Chem Int Ed Engl. 2010 Aug 23;49(36):6258-9. doi: 10.1002/anie.201002867. No abstract available.

PMID:
20648509
11.

Delivery of RNA interference therapeutics using polycation-based nanoparticles.

Howard KA.

Adv Drug Deliv Rev. 2009 Jul 25;61(9):710-20. doi: 10.1016/j.addr.2009.04.001. Epub 2009 Apr 5. Review.

PMID:
19356738
12.

LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI.

Kim SH, Jeong JH, Lee SH, Kim SW, Park TG.

Bioconjug Chem. 2008 Nov 19;19(11):2156-62. doi: 10.1021/bc800249n.

PMID:
18850733
13.
14.

Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate.

Meyer M, Dohmen C, Philipp A, Kiener D, Maiwald G, Scheu C, Ogris M, Wagner E.

Mol Pharm. 2009 May-Jun;6(3):752-62. doi: 10.1021/mp9000124.

PMID:
19348503
15.

A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.

Wang XL, Xu R, Lu ZR.

J Control Release. 2009 Mar 19;134(3):207-13. doi: 10.1016/j.jconrel.2008.11.010. Epub 2008 Nov 27.

PMID:
19135104
16.

Polycation-based nanoparticle delivery for improved RNA interference therapeutics.

Howard KA, Kjems J.

Expert Opin Biol Ther. 2007 Dec;7(12):1811-22. Review.

PMID:
18034647
17.

Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers.

Davis ME, Pun SH, Bellocq NC, Reineke TM, Popielarski SR, Mishra S, Heidel JD.

Curr Med Chem. 2004 Jan;11(2):179-97. Review.

PMID:
14754416
18.

In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.

Malek A, Merkel O, Fink L, Czubayko F, Kissel T, Aigner A.

Toxicol Appl Pharmacol. 2009 Apr 1;236(1):97-108. doi: 10.1016/j.taap.2009.01.014. Epub 2009 Jan 29.

PMID:
19371615
19.

Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.

Eifler AC, Thaxton CS.

Methods Mol Biol. 2011;726:325-38. doi: 10.1007/978-1-61779-052-2_21.

PMID:
21424459
20.

Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.

Li SD, Huang L.

Curr Opin Investig Drugs. 2008 Dec;9(12):1317-23. Review.

PMID:
19037838

Supplemental Content

Support Center